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Abstract A critical analysis of the changes in fatty acid
patterns and their metabolism elicited by vitamin E deficiency
leads to the proposal that a major role of dietary RRR-K-
tocopherol (K-TOC) is as an enzymatic precursor of K-
tocopherolquinone (K-TQ) whose semiquinone radical functions
as an essential enzyme cofactor for the fatty acid desaturases of
the recently elucidated carnitine-dependent, channeled, mito-
chondrial desaturation-elongation pathway; a detailed mecha-
nism for its function is proposed. Pathophysiological states
produced by vitamin E deficiency and K-TOC transfer protein
defects, such as ataxia, myopathy, retinopathy, and sterility are
proposed to develop from the effects of impaired K-TQ-
dependent desaturases and the resulting deficiency of their
polyenoic fatty acid products.
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1. Introduction
Among the repertoire of antioxidant defenses of biological
systems [1,2], RRR-K-tocopherol (K-TOC) is a well established
chain-breaking antioxidant [1,2]. However, increasing evi-
dence suggests that tocopherols are involved in the control
of cell proliferation and di¡erentiation [3] ; K-TOC also func-
tions as a scavenger of active nitrogen species [4] and a Q-
tocopherol metabolite (LLU-K) is a natriuretic factor [5]. In
addition to its other functions, analysis of previous data sug-
gested that K-TOC or its quinone derivatives are involved in
fatty acid desaturation [6,7]. A critical analysis of additional
experimental evidence leads to the proposal that a major role
of dietary K-TOC in mammalian systems is as a precursor of
its D-K-tocopherolquinone (K-TQ) metabolite whose semiqui-
none radical is required as an essential enzyme cofactor by the
recently elucidated carnitine-dependent, channeled mitochon-
drial fatty acid desaturases; a detailed testable mechanism for
this function is proposed.
2. Metabolic characteristics of the mitochondrial desaturation
pathways
The metabolic characteristics of the mitochondrial carni-
tine-dependent channeled multifunctional desaturation-elon-
gation pathway, and the conventional microsomal desatur-
ases, have been described [7,8]. Brie£y, 22:6n33 is proposed
to be synthesized solely by the mitochondrial pathway, while
20:4n36, 20:5n33 (and their elongation products 22:4n36
and 22:5n33, respectively) and 22:5n36 can be synthesized
by both the microsomal and mitochondrial pathways. Various
lines of evidence indicate that the n36 and n33 fatty acids
undergo desaturation-elongation reactions by independent n-
series-speci¢c enzyme systems, and without involvement of 24-
carbon fatty acids as intermediates [7,8]. In addition to its
carnitine requirements, the channeled nature of the mitochon-
drial pathway is characterized by lack of incorporation of the
v6-desaturation-elongation intermediates, such as 18:3n36
and 20:3n36 (or 18:4n33 and 20:4n33), into phospholipids;
these intermediates would remain bound to the multifunction-
al desaturase and, therefore, would not be available to phos-
pholipid acyltransferases [7,8]. Under normal physiological
conditions both pathways appear to operate concomitantly.
However, tracer studies suggest that the channeled mitochon-
drial pathway carries most of the biosynthetic £ux for
20:4n36 and 20:5n33, since these fatty acids are labeled
faster than their conventional microsomal v6-desaturation-
elongation precursors when cell cultures are incubated with
labeled 18:2n36 or 18:3n33 in the presence of lactate (as a
source of intramitochondrial acetyl-CoA via lactate and pyr-
uvate dehydrogenases), and addition of unlabeled intermedi-
ates does not produce the isotopic trapping e¡ects readily
observed for open pathways; this channeling e¡ect is in-
creased by the addition of carnitine to the culture medium
[7,8], further supporting the mitochondrial location of this
channeled desaturation pathway, since fatty acids are trans-
ported into mitochondria as carnitine esters thus favoring the
mitochondrial pathways. In vivo experiments have also shown
a similar channeled synthesis of 22:6n33; pulse chase studies
with labeled 18:3n33 show higher label incorporation into rat
liver 22:6n33 than into its conventional upstream precursors,
i.e. 20:4n33 and 22:5n33, under a variety of dietary condi-
tions [9]. A major role of the microsomal pathway may be to
synthesize low concentrations of eicosanoid precursors, such
as 18:3n36 and 20:3n36, as a consequence of its separate
desaturation and elongation systems. Depending on the met-
abolic control design, these two pathways may be interregu-
lated as compensatory-redundant systems for the synthesis of
fatty acids such as 20:4n36, 22:5n36 and 20:5n33 in some
tissues. As deduced from the e¡ects of lactate indicated above,
another characteristic of the mitochondrial desaturation-elon-
gation pathway is its independence from malonyl-CoA (in
contrast to the microsomal system), with preferential incorpo-
ration of mitochondrially generated acetate (such as acetyl-
carnitine), rather than exogenous acetate, into its fatty acid
products, even though exogenous acetate is readily incorpo-
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rated by the malonyl-CoA-dependent microsomal elongation
system [8]. Recent in vivo evidence has con¢rmed the role of
acetyl-carnitine in the synthesis of brain 20:4n36 and
22:6n33 [10].
3. E¡ects of vitamin E de¢ciency on polyunsaturated fatty acid
patterns
The relative rates of peroxidation of unsaturated fatty acids
containing from 1^6 double bonds have been determined to be
in the ratio of 0.16:1:1.4:2:2.4:2.8 [11] ; therefore, vitamin E
de¢ciency would be expected to produce decreases of unsatu-
rated fatty acids following these ratios if vitamin E functions
only as an antioxidant. However, vitamin E de¢cient diets are
known to elicit changes in phospholipid fatty acids which do
not follow the above peroxidation kinetics; these e¡ects have
been shown by in vitro and in vivo experimental approaches
[12,13]. Rat testis phospholipids display a characteristic fatty
acid pattern after sexual maturation; 22:5n36 is increased
several-fold after puberty, while levels of 22:6n33 are low
and remain unchanged [14,15]. Vitamin E de¢ciency is known
to produce reduced sperm motility with eventual development
of sterility in a variety of mammalian species [16] ; in the rat,
these physiological changes are accompanied by striking alter-
ations in the fatty acid composition of testicular phospholip-
ids, in which levels of 22:5n36 are drastically decreased while
20:4n36 and 22:4n36 (the apparent n36v4-desaturase pre-
cursor) are increased [17,18]. However, when vitamin E de¢-
cient diets contain 22:6n33, the testicular concentration of
this fatty acid is not decreased in rats [17,18], even though
loss of this fatty acid in vitamin E de¢ciency would be ex-
pected due to its high peroxidation potential. These data
clearly indicate that the decreases of testicular 22:5n36 ob-
served in vitamin E de¢cient rats are not primarily from per-
oxidation losses but from impaired de novo biosynthesis.
While rat testis does not appear to synthesize 22:6n33, this
fatty acid is actively synthesized by skeletal muscle; when rats
are fed a vitamin E de¢cient diet containing only the 18-car-
bon essential fatty acids, the resulting myopathic skeletal
muscle shows striking decreases in 22:6n33, while 20:4n36
and the apparent n33v4-desaturase precursor 22:5n33 are
increased [19]. Again, these fatty acid changes can not be
explained by their relative peroxidation rates, which suggests
that the observed decreases in muscle 22:6n33 elicited by
vitamin E de¢ciency are actually from impaired biosynthesis.
4. E¡ects of vitamin E de¢ciency on metabolism of
polyunsaturated fatty acids
The increases in testicular 22:5n36 observed during puber-
ty in the rat [18] are accompanied by striking decreases in
conventional microsomal v6- and v5-desaturase activities
[18,20,21]. These observations have led to the proposal that
an androgen-controlled, channeled, carnitine-dependent mito-
chondrial desaturation pathway, rather than the conventional
microsomal desaturation-elongation pathway, is largely re-
sponsible for the synthesis of rat testicular 22:5n36 [7]; sev-
eral lines of evidence indicate that this pathway preferentially
uses intramitochondrial acetate sources, while the convention-
al microsomal desaturation-elongation pathway has better ac-
cess to exogenous acetate [8]. During vitamin E de¢ciency the
channeled mitochondrial desaturation pathway appears to be
severely impaired, while microsomal desaturation-elongation
is activated as a compensatory response. Consistent with this
proposal is the observation that incorporation of exogenous
[14-C]acetate into rat testicular 20:4n36 and 22:4n36 is in-
creased during vitamin E de¢ciency [22] ; similar increases of
labeled acetate incorporation are observed in muscle 20:4n36
and 22:5n33, but not into 22:6n33 [19]. Vitamin E de¢cient
diets also increase liver microsomal v6- and v5-desaturases,
with increased labeled acetate incorporation into 20:4n36
[23^25]. These ¢ndings, taken together, are consistent with
an activation of the microsomal vitamin E-independent path-
way as a compensatory response to impairment of the vitamin
E-dependent mitochondrial pathway in these tissues. There-
fore, the decreases in rat testicular 22:5n36 and muscle
22:6n33 by vitamin E de¢ciency are predicted by impairment
of the mitochondrial pathway, while the increases in liver
20:4n36, testicular 20:4n36 and 22:4n36, and muscle
20:4n36 and 22:5n33, are expected as a result of activation
of the microsomal pathway in these tissues. The net result of
the interrelationship between these two pathways is an appar-
ent impairment of the v4-desaturation step of both n36 and
n33 fatty acid series by vitamin E de¢ciency, as has been
previously noted [6] ; mitochondrial synthesis of 20:4n36
would also be impaired, but this decrease appears to be com-
pensated by up-regulation of the microsomal pathway in these
rat tissues. In some instances, a small increase in 22:5n36 has
been observed in vitamin E de¢cient skeletal muscle [26], sug-
gesting a compensatory up-regulation of microsomal synthesis
of this fatty acid in type I ¢bers; however, in tissues such as
rat testes where microsomal desaturation is dramatically
down-regulated upon sexual maturation [20,21], the impaired
mitochondrial synthesis of 22:5n36 in vitamin E de¢ciency
does not appear to be compensated for by up-regulation of
microsomal synthesis of this fatty acid. The above data
strongly argue for a coenzyme role of vitamin E in the mito-
chondrial desaturation pathways.
5. Proposed involvement of K-tocopherolquinone in fatty acid
desaturation
It has long been known that both K-TQ and its hydroqui-
none (K-TQH2) have vitamin E activity [27^29], even though
these quinones are not converted to K-TOC [30,31]. Both K-
TQ and K-TQH2 are found in low concentrations in many
tissues [32,33]; however, since they are known to be formed
as one of the byproducts of K-TOC oxidation during perox-
idation reactions in in vitro systems [34,35], it is commonly
believed that this is their only origin. These quinones are,
however, also known to be enzymatically synthesized by pho-
tosynthetic organisms via two routes: from K-TOC [36,37]
and also by de novo synthesis [38,39]; the latter route must
be the one utilized by non-photosynthetic microorganisms
since they make K-TQ but not K-TOC [40]. There are some
data showing that mammalian tissues are also able to synthe-
size K-TQ via the de novo pathway [31], and this quinone may
also be enzymatically synthesized from K-TOC as it is rapidly
formed from labeled K-TOC [41]. Since mammals do not ap-
pear to convert K-TQ to K-TOC [30,31], the signi¢cance of the
above evidence has been overlooked. As mitochondria contain
most of the K-TOC and K-TQ in mammalian tissues
[31,42,43], with the outer membrane containing the majority
of K-TOC [42,44,45], it is likely that K-TQ is also enzymati-
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cally synthesized from dietary K-TOC by a mitochondrial en-
zyme system in the outer membrane. Interestingly, the mito-
chondrial outer membrane, which does not have the high
oxidative reactions of the electron transport chain of the inner
membrane, contains a signi¢cantly lower concentration of un-
saturated phospholipids [13,44,46] ; therefore the higher K-
TOC concentration in the outer membrane is not likely to
be due to higher antioxidant needs. Signi¢cantly, K-TQH2
has been implicated as a hydrogen donor for fatty acid satu-
ration by rumen bacteria [47]. Therefore, it is plausible that K-
TQ might be involved in the reverse reaction, i.e. fatty acid
desaturation, by mitochondrial desaturases since mitochon-
dria evolved from endosymbiotic prokaryotes [48].
In light of the data discussed above, it is proposed that K-
TQ is involved as an enzyme cofactor in the channeled mito-
chondrial desaturation pathway located in the mitochondrial
outer membrane; therefore, a major function of K-TOC in
mammalian tissues would be as a precursor of K-TQ for
this coenzyme function. The essential steps of this mechanism
are depicted in Fig. 1; the initial reaction starts with the bind-
ing of the fatty acid substrate to the desaturase active site
followed by the simultaneous NADH-driven one-electron re-
ductions (via cytochrome b5) of two aligned enzyme-bound K-
tocopherolquinones, i.e. NADH-quinone oxidoreductase reac-
tions, to form the respective stabilized semiquinone radicals,
which would then stereospeci¢cally abstract two hydrogen
atoms from the fatty acid substrate in a concerted reaction
to form the cis-unsaturated product, plus two K-tocopherol-
hydroquinones which eventually transfer their four hydrogens
to molecular oxygen to form two molecules of water, thus
regenerating the respective K-tocopherolquinones for the
next enzyme cycle. The initial electron £ow may occur
through intermediate steps; for instance, the transfer of
NADH-originated electrons from cytochrome b5 to the desa-
turase and to the two K-tocopherolquinones may occur via
FADH2 and iron-sulfur or iron-selenium clusters using a sim-
ilar mechanism to that of the NADH-ubiquinone oxidoreduc-
tase of the respiratory chain [49] ; if so, the K-TQ semiquinone
anion radical may be the active species, and protonation may
occur downstream in the reaction sequence. The details of
these reactions would have to be determined experimentally.
Participation of these iron-sulfur or iron-selenium clusters
would account for the known interaction between vitamin E
and sulfur- and selenium-containing amino acids. The involve-
ment of cytochrome b5 is consistent with its presence in the
outer mitochondrial membrane [50,51] and with the high cy-
tochrome b5 reductase activity (also referred to as rotenone-
insensitive cytochrome C reductase) present in this membrane
[50,52].
An essential feature of the above proposed scheme is that
reduction of molecular oxygen, probably through di-iron cen-
ters [53], occurs downstream of the desaturation step. How-
ever, the transfer of hydrogens to molecular oxygen may not
necessarily occur at the desaturase active site; the two K-
TQH2 products might be released from the desaturase and
re-oxidized by a hydroquinone oxidase. Conversely, the two
K-TQH2 may transfer their hydrogens to mobile carriers such
as free K-TQ or ubiquinone; the reduced form of these car-
riers may shuttle their electrons to the inner membrane mi-
tochondrial respiratory electron transport chain through the
inner-outer membrane contact sites. The postulated hy-
drocarbon oxidizing properties of the semiquinones is plausi-
ble in view of the fact that K-TOC radicals appear to engage
in such hydrogen withdrawal reactions, which accounts for
the pro-oxidant activity of K-TOC observed at high concen-
trations (reviewed in [54]). The oxidizing activity of the K-
TOC radical may be due to the stability conferred by its semi-
quinone-like resonance structure [55]; other semiquinones
which participate in oxidation-reduction reactions are known
to be stabilized at the active site of these enzymes [56^59].
These observations lend further support to the postulation
that K-TQ semiquinone radicals are the active cofactor species
involved in the desaturation reaction.
The proposed site of synthesis of K-TQ in the same mem-
brane where the desaturase is postulated to be located (mito-
chondrial outer membrane) is dictated by the known instabil-
ity of quinones; this would explain the ¢nding that this
quinone can substitute for K-TOC when administered in fre-
quent and small concentrations [28,29]. The known resistance
to vitamin E de¢ciency by some species, such as mice and
some rats [60,61], is proposed to occur by e⁄cient up-regula-
tion of endogenous de novo K-TQ synthesis ; because of re-
current periods of starvation the structural and regulatory
genes for its enzymatic machinery may have been conserved
in these facultative omnivore species. Enzymatic synthesis of
K-TQ from K-TOC is also likely to be up-regulated by vitamin
E de¢ciency as a compensatory response. Consistent with this
proposition is the observation that this conversion is increased
in vitamin E de¢cient rats [62]. However, in herbivora the
ability to make K-TQ from de novo synthesis was probably
lost by genetic drift because of the abundant supply of K-TOC
in their natural leafy diet; therefore, these species may only be
able to make K-TQ from dietary K-TOC, explaining their
known high susceptibility to vitamin E de¢ciency [63,64], a
fact di⁄cult to explain if K-TOC were to function only as
an antioxidant.
The above proposed stereospeci¢c hydrogen abstraction
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Fig. 1. Proposed mechanism of action for K-tocopherolquinone (K-
TQ) as a speci¢c cofactor for the mitochondrial desaturases. The re-
action sequence is initiated by binding of the fatty acid substrate to
the enzyme active site followed by the simultaneous NADH-driven
one-electron reductions of two aligned enzyme-bound K-tocopherol-
quinones to form the respective stabilized semiquinone radicals,
which then stereospeci¢cally abstract two hydrogen atoms from the
fatty acid substrate in a concerted reaction to form the cis-unsatu-
rated fatty acid product and two K-tocopherolhydroquinones; these
reduced quinones eventually transfer their four hydrogens to molec-
ular oxygen to form two molecules of water, thus regenerating the
respective K-tocopherolquinones for the next catalytic cycle. Other
details and possible intermediates of this mechanism are described
in Section 5.
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mechanism accounts for the concerted formation of cis-unsat-
urated bonds, an exquisite power of fatty acid desaturases
[65], for which a mechanism has not been previously pro-
posed. Since the microsomal fatty acid desaturases are also
known to introduce cis-double bonds, they may operate via a
similar concerted mechanism. If so, since these desaturases do
not appear to be dependent on K-TQ, their active site may
contain other quinones, such as ubiquinone; the identity of
these proposed alternative quinones remains to be elucidated.
Their di-iron centers [53] may only participate in the ¢nal step
of electron transfer to molecular oxygen.
6. Conclusion
Vitamin E was discovered more than 75 years ago [66].
Soon after the structures of the various tocopherols were elu-
cidated, it was realized that this vitamin or its quinone deriv-
atives would likely be involved in oxidation-reduction reac-
tions [28,67]. A search for an enzyme cofactor function
involving such reactions was sought but never substantiated.
It is hoped that the above proposed involvement of K-TQ in
fatty acid desaturation represents one of the long-sought en-
zymatic functions of this vitamin. The pathophysiological
states of ataxia, myopathy and retinopathy in metabolic dis-
eases associated with vitamin E de¢ciency [68,69], such as
abetalipoproteinemias, cholestasis, cystic ¢brosis, and genetic
defects in the synthesis of K-TOC transfer protein [70,71], are
likely to be due to de¢ciency of the main enzymatic products
of the channeled mitochondrial K-TQ-dependent desatura-
tion-elongation pathway, such as 20:4n36 and 22:6n33.
Phospholipids containing these fatty acids have been proposed
to play essential roles as tightly bound conformational cofac-
tors for myelogenesis, ion pumps and other membrane pro-
teins [7,8,72]; recent ¢ndings [73] have con¢rmed the postu-
lated role of 22:6n33 in myelin synthesis. Therefore,
administration of these fatty acids may have therapeutic value
for patients with these devastating disorders. Because im-
paired lipid absorption is associated with some of these dis-
eases, providing these fatty acids esteri¢ed to phospholipids,
such as phosphatidylcholine, might improve their absorption.
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